Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $112.80 Consensus Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received a consensus recommendation of “Buy” from the twenty-two brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $114.45.

KYMR has been the subject of a number of research analyst reports. B. Riley increased their target price on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 24th. Bank of America upped their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. lifted their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Wednesday, October 8th. Finally, Guggenheim assumed coverage on Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 target price on the stock.

Insider Activity

In other Kymera Therapeutics news, insider Jared Gollob sold 59,576 shares of Kymera Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the completion of the transaction, the insider owned 109,992 shares in the company, valued at approximately $6,755,708.64. The trade was a 35.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 229,809 shares of the stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the completion of the sale, the director owned 686,477 shares in the company, valued at $62,970,535.21. This represents a 25.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 488,585 shares of company stock worth $41,408,199 in the last three months. Company insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $79.63 on Friday. The company has a market cap of $5.73 billion, a P/E ratio of -22.18 and a beta of 2.28. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The business has a fifty day moving average of $66.85 and a two-hundred day moving average of $53.34.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The company had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. Sell-side analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.